KaiBiLi Flu&Covid-19 Antigen Duo Rapid Test
Introduction
Clinical signs and symptoms of respiratory viral infection due to SARS-CoV-2 and influenza can be similar. SARS-CoV-2, influenza A and influenza B viral antigens are generally detectable in upper respiratory specimens during the acute phase of infection.
Influenza virus belongs to the family of Orthomyxoviridae, and immunologically diverse, single-stranded RNA viruses. There influenza A and B virus is the main pathogen that severe illnesses both in human and in many animal species. Based on the current epidemiological investigation, the incubation period is 1 to 4 days. The main manifestations include acute fever, general aching and respiratory symptoms. Both Type A and B viruses can circulate simultaneously, but usually one type is dominant during a given season.1
COVID-19 is an acute respiratory infectious disease. People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.
KaiBiLiTM Flu & COVID-19 Antigen Duo Rapid Test is intended for the simultaneous qualitative detection and differentiation of the nucleocapsid protein antigens from SARS-CoV-2, influenza A and influenza B in direct nasopharyngeal (NP) specimens. The detection is based on the antibodies which were developed specifically recognizing and reacting with the nucleoprotein of virus.
Detection
KaiBiLiTM Flu & COVID-19 Antigen Duo Rapid Test is the simultaneous qualitative detection and differentiation of the nucleocapsid protein antigens from SARS-CoV-2, influenza A and influenza B in direct nasopharyngeal (NP) specimens.
Specimen
Nasopharyngeal
Limit of Detection (LoD)
SARS-CoV-2 & Flu: 140 TCID50/mL
Influenza A
Influenza Viral Strain |
Calculated LOD (TCID50/mL) |
A/New Caledonia/20/1999_H1N1 |
8.50x103 |
A/California/04/2009_H1N1 |
2.11x103 |
A/PR/8/34_H1N1 |
2.93x103 |
A/Bean Goose/Hubei/chenhu XVI35-1/2016_H3N2 |
4.94x102 |
A/Guizhou/54/89_H3N2 |
3.95x102 |
A/Human/Hubei/3/2005_H3N2 |
2.93x104 |
A/Bar-headed Goose/QH/BTY2/2015_H5N1 |
1.98x105 |
A/Anhui/1/2013_H7N9 |
7.90x105 |
Influenza B.
Influenza Viral Strain |
Calculated LOD (TCID50/mL) |
B/Victoria |
4.25x103 |
B/Yamagata |
1.58x102 |
Accuracy
Influenza A | Influenza B | COVID-19 | |
Relative Sensitivity | 86.80% | 91.70% | 96.60% |
Relative Specificity | 94% | 97.50% | 100% |
Accuracy | 92.20% | 96.10% | 98.90% |
Time to Results
Read results at 15minutes and no more than 30 minutes.
Kit storage conditions
2~30°C.
Contents
Test devices | 20 tests |
Sterilized swabs | 20 pcs. |
Extraction tubes (with 0.5mL extraction buffer) | 20 pcs. |
Nozzle with filter | 20 pcs. |
Tube Stand | 1 pcs. |
Package Insert | 1 pcs. |
Ordering Information
Product |
Cat.No. |
Contents |
KaiBiLiTM Flu & COVID-19 Antigen Duo |
P211137 |
20 Tests |